Shopping Cart 0
Cart Subtotal
USD 0

Eisai Co Ltd (4523) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Eisai Co Ltd (Eisai) is a pharmaceutical company that undertakes the research, development, manufacture and marketing of pharmaceuticals, including over-the-counter (OTC) drugs, prescription medicines and generics. The company's franchise areas in research include neurology and oncology. Eisai's major products include Pariet/AcipHex (proton pump inhibitor); Aricept, an anti-Alzheimer's agent; Halaven, a novel anti-cancer agent; Fycompa, an anti-epileptic and peripheral neuropathy treatment, among others. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

Eisai Co Ltd (4523)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 8

List of Figures 10

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Eisai Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14

Eisai Co Ltd, Medical Devices Deals, 2012 to YTD 2018 16

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deal Details 24

Asset Purchase 24

Eisai to Acquire Rights of Kolbet from Toyoma Chemical and Taisho Pharma 24

Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 25

Partnerships 26

Distributed Bio Enters into Collaboration with H3 Biomedicine 26

Eisai and MSD Enter into Co-Marketing Agreement 27

KAN Research Institute Enters into Development Agreement with Six Research Organizations 28

Eisai Enters into Research Agreement with Broad Institute, Colorado State University and University of Chicago 30

Eisai Enters into Development Agreement with Sloan Pharma 31

Eisai Enters into Agreement with Nichi-Iko Pharma 32

Eisai Enters into Co-Development and Co-Commercialization Agreement with Merck 33

Eisai and Boston University School of Medicine Enter into Research Agreement 34

Morphotek Enters into Research Agreement with Rockefeller University 35

Eisai Enters into Co-Promotion Agreement with Biogen 36

Sato Pharma, Eisai and Seren Pharma Enter into Agreement 37

EA Pharma and Mochida Pharma Enter into Joint Development Agreement 38

Ono Pharma Enters into Agreement with Eisai 39

Eisai Enters into Agreement with Merck 40

Morphotek Enters into Agreement with Johns Hopkins University School of Medicine 41

Eisai Enters into Agreement with Merck for Eribulin 42

Eisai Enters into Research Agreement with Broad Institute 43

Ewopharma and Eisai Enter into Co-Marketing Agreement 44

Oncology Venture and Eisai Enter into Agreement 45

Eisai Enters into Marketing and Distribution Agreement with Orion 46

Eisai Enters into Agreement with Keio University 47

Eisai Enters into Research Agreement with Oklahoma Medical Research Foundation 48

Morphotek Enters into Research Agreement with Fox Chase Cancer Center 49

Cancer Genetics Partners with H3 Biomedicine 50

Novartis Pharma Enters into Agreement with Eisai 51

EA Pharma Enters into Co-Promotion Agreement with AbbVie 52

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 53

Eisai Forms Joint Venture with Ajinomoto 55

Morphotek Enters into Agreement with Areva Med 56

Ajinomoto Pharma and Mochida Pharma Enter into Co-Development Agreement 57

Eisai Enters into Agreement with PIQUR Therapeutics 58

Eisai Extends Research Agreement with Charles River Labs 59

Eisai Enters into Agreement with Esteve 60

Morphotek Enters into Agreement with Mayo Clinic 61

Morphotek Enters into Research Agreement with University of Wisconsin Madison 62

Morphotek Enters into R&D Agreement with Targeted Alpha Therapy 63

Eisai Enters into Research Agreement with Medicines for Malaria Venture 64

Eisai Enters into Research Agreement with Liverpool School of Tropical Medicine and University of Liverpool 65

Eisai Enters into Research Agreement with Paoli Calmettes Institute 66

Eisai Enters into Agreement with Purdue Pharma 67

JCR Pharma Enters into Agreement with Eisai 68

Eisai Enters into Agreement with Nihon Medi-Physics 69

Kissei Pharma Enters into Co-Development Agreement with Ajinomoto Pharma 70

Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 71

AbbVie Deutschland Enters into Partnership Agreement with Eisai 72

Hikma Pharma Enters into Distribution Agreement with Eisai for Fycompa 73

Eisai Enters into Research Agreement with St. Jude Children's Research Hospital and Medicines For Malaria Venture to Develop SJ733 74

Eisai Enters into Research Agreement with Broad Institute 75

Eisai Enters into Agreement with Kyorin 76

Stealth Biologics Enters into Co-Development Agreement with Morphotek 77

Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek 78

Eisai and University of Tsukuba Enter into Co-Development Agreement 79

Eisai Enters Co-Development Agreement With Liverpool School Of Tropical Medicine And University of Liverpool 80

Eisai Expands Co-Development Agreement with Biogen 81

Eisai Enters into Co-Marketing Agreement with Esteve for Zonegran 83

Eisai Enters Into Co-Marketing Agreement With NewBridge Pharma For Halaven (Eribulin) 84

Eisai Enters Into Co-Development Agreement With Broad Institute For Neglected Tropical Diseases And Tuberculosis 85

Eisai Amends its Co-Marketing Agreement with Arena Pharma for Belviq 86

H3 Biomedicine Extends Agreement with Selvita 88

H3 Biomedicine And BGI Enter Into Agreement To Develop And Share Cancer Genomic Sequencing Data 89

H3 Biomedicine Enters Into Agreement With Sage Bionetworks For Cancer-Genomics Research 90

Eisai Enters Into Drug Discovery Agreement With University College London For Neurological Drugs 91

RaQualia Pharma Enters into Research Agreement with Ajinomoto Pharma 92

Eisai Enters Into R&D Agreement With Oswaldo Cruz Foundation For Malaria And Neglected Tropical Diseases 93

Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 94

Eisai Enters Into Agreement With Sabin Vaccine Institute To Develop Vaccines For Neglected Tropical Diseases 95

Verastem Enters Into Research Agreement With Eisai For Small Molecule Wnt Inhibitors 96

Galenea Enters Into Agreement With Eisai To Develop Synaptic Modulators for Neurodegenerative Diseases 97

MicroBiopharm Japan Enters Into Co-Development Agreement With Eisai 98

Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin 99

Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine 100

Proteros Biostructures Enters Into Drug Discovery Agreement With Eisai 101

Eisai Europe Enters Into Distribution Agreement With PharmaSwiss For Halaven 102

NanoCarrier Enters Into Co-Development Agreement With Eisai 103

Licensing Agreements 104

Eurofarma Labs Enters into Licensing Agreement with Eisai 104

BioArctic Receives Rights from Eisai 105

CY Biotech Enters into Licensing Agreement with Eisai 106

Tasly Pharma Enters into Licensing Agreement with EA Pharma 107

Morphotek Enters into Licensing Agreement with Bliss Biopharma 108

EA Pharma to Enter into Licensing Agreement with Cosmo Technologies 109

Adlai Nortye Biopharma Enters into Licensing Agreement with Eisai 110

JW Pharma Enters into Licensing Agreement with EA Pharma 111

Grupo Biotoscana Enters into Licensing Agreement with Eisai 112

Oncology Venture Enters into Licensing Agreement with Eisai 113

Eisai Enters into Licensing Agreement with Meiji Seika Pharma 114

EA Pharma Enters into Licensing Agreement with Calypso Biotech 115

Morphotek Enters into Licensing Agreement with Eurofarma Laboratorios 116

Dr. Reddy's Labs Enters into Licensing Agreement with Eisai for E7777 117

HUYA Bioscience International Enters into Licensing Agreement with Eisai 118

Eisai Enters into License Agreement with Amplyx Pharma 119

Roivant Sciences Enters into Licensing Agreement with Eisai 120

Blaze Bioscience Enters into Licensing Agreement with Morphotek 121

LTT Bio-Pharma Enters into License Agreement with Ajinomoto Pharma 122

Lantern Pharma Enters into Licensing Agreement with Eisai 123

Boston Strategics Enters into Licensing Agreement with Eisai for E6201 124

NanoCarrier Enters into Licensing Agreement with Eisai 125

Ajinomoto Pharma Amends Licensing Agreement with Albireo for Elobixibat 126

Otsuka Pharma Enters Into Licensing Agreement With Eisai 127

Accellta Enters into Licensing Agreement with Ajinomoto 128

Eisai To Enter Into Licensing Agreement With Nobelpharma For Antineoplastic Agent Gliadel 7.7Mg Implant 129

Eisai Enters Into Licensing Agreement With Generic Drug Manufacturer For Donepezil HCl 23mg 130

Ildong Enters Into Licensing Agreement With Ajinomoto Pharma For Cilnidipine/Valsartan Drug 131

Santen Pharma And Eisai Enter Into Option Agreement For Ophthalmic Drugs 132

Eisai Enters Into Licensing Agreement With Minophagen Pharma For Bexaroten 133

Institute for OneWorld Health Enters Into Licensing Agreement With Eisai For Pro-Drug Technology Patent 134

Compendia Bioscience Enters Into Licensing Agreement With H3 Biomedicine 135

Asset Transactions 136

Riemser Pharma Acquires European Rights to Prialt from Eisai 136

Concordia Pharmaceuticals Acquires Zonegran from Eisai for USD91.5 Million 137

Sarepta Therapeutics to Acquire Manufacturing Plant in Massachusetts from Eisai for USD15 Million 139

Eisai Taiwan Sells Tainan Production Plant To Bora 140

Valeant Pharma Acquires US Rights To Targretin From Eisai 141

Arbor Pharma To Acquire US Rights For Gliadel Wafer From Eisai 142

Acquisition 144

Dova Pharma Acquires AkaRx from Eisai 144

Eisai Acquires Liaoning TianYi Biological Pharma for USD78 Million 146

Alfresa to Acquire Sannova from Eisai 147

Sekisui Chemical to Acquire Eidia from Eisai for USD182 Million 148

Robert Bosch Completes Acquisiton Of Eisai Machinery 149

Eisai Co Ltd - Key Competitors 151

Eisai Co Ltd - Key Employees 152

Eisai Co Ltd - Locations And Subsidiaries 155

Head Office 155

Other Locations & Subsidiaries 155

Joint Venture 157

Recent Developments 159

Strategy And Business Planning 159

Nov 08, 2018: Eisai commences full-scale operation of new suzhou plant in China 159

Jun 13, 2018: Eisai To Establish New Research Facility Eisai Center For Genetics Guided Dementia Discovery In Cambridge, Massachusetts In The United States 160

Jan 11, 2018: Eisai Completes Construction Of Oral Solid Dose Production Facility At New Suzhou Plant In China 161

Corporate Communications 162

Oct 10, 2018: Eisai to support earthquake relief efforts in sulawesi, indonesia 162

Jul 18, 2018: Eisai supports relief efforts for flooding in western Japan 163

Jun 11, 2018: Eisai Names Lihua Yu As President & Chief Data Sciences Officer Of H3 Biomedicine 164

Sep 25, 2017: Eisai to Contribute to Central Mexican Earthquake Relief Efforts 165

Apr 05, 2017: Eisai and Meiji to commercialise safinamide for Parkinsons disease in Japan and Asia 166

Government and Public Interest 167

Oct 31, 2017: GHIT Fund Accelerates Promising Efforts to Find New Treatments, Vaccines and Diagnostics for Malaria, Tuberculosis, Leishmaniasis and Mycetoma 167

Jun 28, 2017: Eisai Listed for 16th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment 170

Jan 18, 2017: Eisai To Participate In Access Accelerated, Global Partnership To Address Rise Of Non-Communicable Diseases 171

Product News 172

12/07/2017: Eisai and Purdue Pharma L.P. Presented Lemborexant Data from Research Studies at ACNP Annual Meeting 172

10/31/2017: Eisai To Present Latest Data On lemborexant At 10th Clinical Trials On Alzheimer's Disease 173

10/24/2018: Eisai to present discovery of a structurally novel class of STING agonist E7766 at SITC's 33rd Annual Meeting 174

Oct 19, 2018: Discovery of candidate compound as potential treatment for parkinson's disease using ips cellsopening the way to establishing new techniques for developing treatments for neurological diseases 175

Oct 10, 2017: Small And Easy To Take, Just One Tablet Per Dose Eisai To Launch Onji-No-Megumi For Improving Forgetfulness In Middle Age And Beyond 177

09/11/2017: Eisai Presents Results of Phase Ib/II Clinical Study of Lenvima in Combination With Pembrolizumab for Renal Cell Carcinoma in Oral Session at ESMO 2017 Congress 178

07/17/2017: Eisai Presents Poster on BAN2401 at the 2017 Alzheimer's Association International Conference 180

06/15/2017: Inhibitor Drug Improves Overall Survival in Older Radioiodine Resistant Thyroid Cancer Patients 181

06/05/2017: Eisai to Present Results of Phase Ib/II Study of Anticancer Agent Lenvima (Lenvatinib) in Combination With Anti-PD-1 Antibody Pembrolizumab for the Treatment of Endometrial Carcinoma at 53rd ASCO Annual Meeting 182

06/02/2017: Further Study of Combination of Eisais Lenvatinib and Mercks Pembrolizumab in Previously Treated Patients with Metastatic Endometrial Cancer Supported by Interim Analysis of Ongoing Phase 1b/2 Trial 184

04/05/2017: Eisai Presents Data Of Mechanisms Of Action Relating To Tumor Immune Response Regarding Combination Of Anticancer Agent Lenvatinib With Anti-PD-1 Antibody At AACR 108th Annual Meeting 186

03/28/2017: Eisai to Present Data on Lenvima at 2017 AACR Annual Meeting 187

03/28/2017: German Federal Joint Committee (G-BA) Confirms Additional Benefit of Kisplyx (lenvatinib) in Treatment of Advanced Renal Cell Carcinoma 189

03/23/2018: Anticancer Agent LENVIMA (lenvatinib mesylate) Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC 190

03/12/2018: Grupo Biotoscana Announces New Initiatives for LENVIMA 191

01/09/2018: Eisai and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA (lenvatinib mesylate) and KEYTRUDA (pembrolizumab) as Combination Therapy for Advanced and/or Metastatic Renal Cell Carcinoma 192

01/04/2017: German Institute for Quality and Efficiency in Health Care Confirms Additional Benefit for Kisplyx (lenvatinib) in Combination with everolimus for the Treatment of Advanced Renal Cell Carcinoma 194

01/03/2018: Clinigen Seeks Marketing Authorisation and Launch Lenvima in Africa 196

Product Approvals 197

Feb 16, 2018: UK NICE Recommends Anticancer Agent Lenvima as Treatment for Thyroid Cancer 197

Jan 26, 2018: NICE Issues Technology Appraisal Guidance on Lenvatinib with Everolimus for Previously Treated Advanced RCC 198

Dec 27, 2017: Anticancer Agent Lenvatinib Designated For Priority Review And Approval By China Food And Drug Administration For Hepatocellular Carcinoma 200

Dec 11, 2017: Eisai salutes positive NICE Recommendation for Kisplyx (lenvatinib) for the treatment of advanced renal cell carcinoma 201

Dec 06, 2017: Eisai Submits Application For Expanded Indication Covering Hepatocellular Carcinoma For Anticancer Agent Lenvima In Taiwan 202

Oct 31, 2017: New Drug Application Of Anticancer Agent Lenvatinib For Hepatocellular Carcinoma Accepted In China 203

Sep 27, 2017: Application for Additional Indication of Lenvima for Hepatocellular Carcinoma Accepted for Review by U.S. FDA 205

Sep 26, 2017: FDA Accepts Supplemental New Drug Application for Eisais Lenvatinib for the Treatment of Liver Cancer 207

Jul 25, 2017: Eisai submits simultaneous applications in the united states and europe for lenvatinib in hepatocellular carcinoma 209

Jun 23, 2017: Eisai Submits Application For Additional Indication Of Anticancer Agent Lenvima For Hepatocellular Carcinoma In Japan 210

Clinical Trials 212

Sep 14, 2018: 1.5M to develop candidate drug to treat onchocerciasis and lymphatic filariasis 212

May 22, 2018: Eisai and Purdue Pharma Announce Key Phase 1 Clinical Studies of Lemborexant to be Presented at the 32nd Annual SLEEP Meeting 213

Mar 07, 2018: Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant 215

Feb 15, 2018: Positive Phase 3 Trial Results of Investigational Anticancer Agent Lenvatinib in Unresectable Hepatocellular Carcinoma (HCC) Published in The Lancet 217

Feb 10, 2018: Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in the Lancet 219

Jan 22, 2018: Eisai Presents Results of Analysis of Phase III Trial of Lenvima (Lenvatinib) In Hepatocellular Carcinoma Based on Independent Imaging Review at ASCO-GI 220

Dec 21, 2017: BioArctic announces that the Phase 2b study of BAN2401 in early Alzheimers Disease continues toward 18 month endpoint 222

Sep 29, 2017: Eisai Presents Results of Phase III Trial of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma in Oral Session at 20th CSCO Annual Meeting 224

Sep 19, 2017: Eisai Presents Results Of Phase III Clinical Study Of Lenvima (Lenvatinib) In Unresectable Hepatocellular Carcinoma At 11th ILCA Annual Conference 226

Sep 11, 2017: Eisai Presents New Quality of Life Findings in Hepatocellular Carcinoma Patients from Lenvatinib Versus Sorafenib Study in Oral Session at ESMO Congress 228

Sep 01, 2017: Eisai to Present 3 Abstracts on Lenvima at ESMO 2017 Congress 230

Sep 01, 2017: Eisai to Present Abstract on E7046 at ESMO 2017 Congress 232

Sep 01, 2017: Eisai to Present Abstract on its Oncology Product Candidate E7046 at the ESMO 2017 Congress 233

Sep 01, 2017: Eisai To Present Abstracts On Oncology Products And Pipeline At ESMO 2017 Congress 234

Aug 28, 2017: Lenvatinib Significantly Improved Overall Survival in Older Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer According to Results of Subanalysis of Phase 3 SELECT Trial 236

Jul 17, 2017: Eisai Presents 3 Posters on E2027 at the 2017 Alzheimer's Association International Conference 238

Jun 05, 2017: Eisai to Present Results of Phase III Trial of Lenvima (Lenvatinib) as First-line Treatment for Unresectable Hepatocellular Carcinoma in Oral Session at 53rd Asco Annual Meeting 239

Jun 04, 2017: Lenvatinib Demonstrates Positive Results vs Sorafenib Across All Endpoints in First-Line Phase 3 Non-inferiority Trial of Unresectable Hepatocellular Carcinoma (uHCC) 241

May 18, 2017: Eisai to Present Abstracts on Lenvatinib At 53rd ASCO Annual Meeting 243

Jan 25, 2017: Phase III Trial Of Anticancer Agent Lenvima As First-Line Treatment For Unresectable Hepatocellular Carcinoma Meets Primary Endpoint 244

Appendix 245

Methodology 245

About GlobalData 245

Contact Us 245

Disclaimer 245


List Of Figure

List of Figures

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 12

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14

Eisai Co Ltd, Medical Devices Deals, 2012 to YTD 2018 16


List Of Table

List of Tables

Eisai Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Eisai Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Eisai Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 14

Eisai Co Ltd, Medical Devices Deals, 2012 to YTD 2018 16

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17

Eisai to Acquire Rights of Kolbet from Toyoma Chemical and Taisho Pharma 24

Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 25

Distributed Bio Enters into Collaboration with H3 Biomedicine 26

Eisai and MSD Enter into Co-Marketing Agreement 27

KAN Research Institute Enters into Development Agreement with Six Research Organizations 28

Eisai Enters into Research Agreement with Broad Institute, Colorado State University and University of Chicago 30

Eisai Enters into Development Agreement with Sloan Pharma 31

Eisai Enters into Agreement with Nichi-Iko Pharma 32

Eisai Enters into Co-Development and Co-Commercialization Agreement with Merck 33

Eisai and Boston University School of Medicine Enter into Research Agreement 34

Morphotek Enters into Research Agreement with Rockefeller University 35

Eisai Enters into Co-Promotion Agreement with Biogen 36

Sato Pharma, Eisai and Seren Pharma Enter into Agreement 37

EA Pharma and Mochida Pharma Enter into Joint Development Agreement 38

Ono Pharma Enters into Agreement with Eisai 39

Eisai Enters into Agreement with Merck 40

Morphotek Enters into Agreement with Johns Hopkins University School of Medicine 41

Eisai Enters into Agreement with Merck for Eribulin 42

Eisai Enters into Research Agreement with Broad Institute 43

Ewopharma and Eisai Enter into Co-Marketing Agreement 44

Oncology Venture and Eisai Enter into Agreement 45

Eisai Enters into Marketing and Distribution Agreement with Orion 46

Eisai Enters into Agreement with Keio University 47

Eisai Enters into Research Agreement with Oklahoma Medical Research Foundation 48

Morphotek Enters into Research Agreement with Fox Chase Cancer Center 49

Cancer Genetics Partners with H3 Biomedicine 50

Novartis Pharma Enters into Agreement with Eisai 51

EA Pharma Enters into Co-Promotion Agreement with AbbVie 52

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 53

Eisai Forms Joint Venture with Ajinomoto 55

Morphotek Enters into Agreement with Areva Med 56

Ajinomoto Pharma and Mochida Pharma Enter into Co-Development Agreement 57

Eisai Enters into Agreement with PIQUR Therapeutics 58

Eisai Extends Research Agreement with Charles River Labs 59

Eisai Enters into Agreement with Esteve 60

Morphotek Enters into Agreement with Mayo Clinic 61

Morphotek Enters into Research Agreement with University of Wisconsin Madison 62

Morphotek Enters into R&D Agreement with Targeted Alpha Therapy 63

Eisai Enters into Research Agreement with Medicines for Malaria Venture 64

Eisai Enters into Research Agreement with Liverpool School of Tropical Medicine and University of Liverpool 65

Eisai Enters into Research Agreement with Paoli Calmettes Institute 66

Eisai Enters into Agreement with Purdue Pharma 67

JCR Pharma Enters into Agreement with Eisai 68

Eisai Enters into Agreement with Nihon Medi-Physics 69

Kissei Pharma Enters into Co-Development Agreement with Ajinomoto Pharma 70

Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 71

AbbVie Deutschland Enters into Partnership Agreement with Eisai 72

Hikma Pharma Enters into Distribution Agreement with Eisai for Fycompa 73

Eisai Enters into Research Agreement with St. Jude Children's Research Hospital and Medicines For Malaria Venture to Develop SJ733 74

Eisai Enters into Research Agreement with Broad Institute 75

Eisai Enters into Agreement with Kyorin 76

Stealth Biologics Enters into Co-Development Agreement with Morphotek 77

Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek 78

Eisai and University of Tsukuba Enter into Co-Development Agreement 79

Eisai Enters Co-Development Agreement With Liverpool School Of Tropical Medicine And University of Liverpool 80

Eisai Expands Co-Development Agreement with Biogen 81

Eisai Enters into Co-Marketing Agreement with Esteve for Zonegran 83

Eisai Enters Into Co-Marketing Agreement With NewBridge Pharma For Halaven (Eribulin) 84

Eisai Enters Into Co-Development Agreement With Broad Institute For Neglected Tropical Diseases And Tuberculosis 85

Eisai Amends its Co-Marketing Agreement with Arena Pharma for Belviq 86

H3 Biomedicine Extends Agreement with Selvita 88

H3 Biomedicine And BGI Enter Into Agreement To Develop And Share Cancer Genomic Sequencing Data 89

H3 Biomedicine Enters Into Agreement With Sage Bionetworks For Cancer-Genomics Research 90

Eisai Enters Into Drug Discovery Agreement With University College London For Neurological Drugs 91

RaQualia Pharma Enters into Research Agreement with Ajinomoto Pharma 92

Eisai Enters Into R&D Agreement With Oswaldo Cruz Foundation For Malaria And Neglected Tropical Diseases 93

Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 94

Eisai Enters Into Agreement With Sabin Vaccine Institute To Develop Vaccines For Neglected Tropical Diseases 95

Verastem Enters Into Research Agreement With Eisai For Small Molecule Wnt Inhibitors 96

Galenea Enters Into Agreement With Eisai To Develop Synaptic Modulators for Neurodegenerative Diseases 97

MicroBiopharm Japan Enters Into Co-Development Agreement With Eisai 98

Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin 99

Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine 100

Proteros Biostructures Enters Into Drug Discovery Agreement With Eisai 101

Eisai Europe Enters Into Distribution Agreement With PharmaSwiss For Halaven 102

NanoCarrier Enters Into Co-Development Agreement With Eisai 103

Eurofarma Labs Enters into Licensing Agreement with Eisai 104

BioArctic Receives Rights from Eisai 105

CY Biotech Enters into Licensing Agreement with Eisai 106

Tasly Pharma Enters into Licensing Agreement with EA Pharma 107

Morphotek Enters into Licensing Agreement with Bliss Biopharma 108

EA Pharma to Enter into Licensing Agreement with Cosmo Technologies 109

Adlai Nortye Biopharma Enters into Licensing Agreement with Eisai 110

JW Pharma Enters into Licensing Agreement with EA Pharma 111

Grupo Biotoscana Enters into Licensing Agreement with Eisai 112

Oncology Venture Enters into Licensing Agreement with Eisai 113

Eisai Enters into Licensing Agreement with Meiji Seika Pharma 114

EA Pharma Enters into Licensing Agreement with Calypso Biotech 115

Morphotek Enters into Licensing Agreement with Eurofarma Laboratorios 116

Dr. Reddy's Labs Enters into Licensing Agreement with Eisai for E7777 117

HUYA Bioscience International Enters into Licensing Agreement with Eisai 118

Eisai Enters into License Agreement with Amplyx Pharma 119

Roivant Sciences Enters into Licensing Agreement with Eisai 120

Blaze Bioscience Enters into Licensing Agreement with Morphotek 121

LTT Bio-Pharma Enters into License Agreement with Ajinomoto Pharma 122

Lantern Pharma Enters into Licensing Agreement with Eisai 123

Boston Strategics Enters into Licensing Agreement with Eisai for E6201 124

NanoCarrier Enters into Licensing Agreement with Eisai 125

Ajinomoto Pharma Amends Licensing Agreement with Albireo for Elobixibat 126

Otsuka Pharma Enters Into Licensing Agreement With Eisai 127

Accellta Enters into Licensing Agreement with Ajinomoto 128

Eisai To Enter Into Licensing Agreement With Nobelpharma For Antineoplastic Agent Gliadel 7.7Mg Implant 129

Eisai Enters Into Licensing Agreement With Generic Drug Manufacturer For Donepezil HCl 23mg 130

Ildong Enters Into Licensing Agreement With Ajinomoto Pharma For Cilnidipine/Valsartan Drug 131

Santen Pharma And Eisai Enter Into Option Agreement For Ophthalmic Drugs 132

Eisai Enters Into Licensing Agreement With Minophagen Pharma For Bexaroten 133

Institute for OneWorld Health Enters Into Licensing Agreement With Eisai For Pro-Drug Technology Patent 134

Compendia Bioscience Enters Into Licensing Agreement With H3 Biomedicine 135

Riemser Pharma Acquires European Rights to Prialt from Eisai 136

Concordia Pharmaceuticals Acquires Zonegran from Eisai for USD91.5 Million 137

Sarepta Therapeutics to Acquire Manufacturing Plant in Massachusetts from Eisai for USD15 Million 139

Eisai Taiwan Sells Tainan Production Plant To Bora 140

Valeant Pharma Acquires US Rights To Targretin From Eisai 141

Arbor Pharma To Acquire US Rights For Gliadel Wafer From Eisai 142

Dova Pharma Acquires AkaRx from Eisai 144

Eisai Acquires Liaoning TianYi Biological Pharma for USD78 Million 146

Alfresa to Acquire Sannova from Eisai 147

Sekisui Chemical to Acquire Eidia from Eisai for USD182 Million 148

Robert Bosch Completes Acquisiton Of Eisai Machinery 149

Eisai Co Ltd, Key Competitors 151

Eisai Co Ltd, Key Employees 152

Eisai Co Ltd, Subsidiaries 155

Eisai Co Ltd, Joint Venture 157

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Eisai Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Eisai Co Ltd (Eisai) is a pharmaceutical company that undertakes the research, development, manufacture and marketing of pharmaceuticals, including over-the-counter (OTC) drugs, prescription medicines and generics. The company's franchise areas in research include neurology and oncology. Eisai's major products include Pariet/AcipHex (proton pump inhibitor); Aricept, an anti-Alzheimer's agent; Halaven, a novel anti-cancer agent; Fycompa, an anti-epileptic and peripheral neuropathy treatment, among others. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

Eisai Co Ltd (4523)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 8

List of Figures 10

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Eisai Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14

Eisai Co Ltd, Medical Devices Deals, 2012 to YTD 2018 16

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deal Details 24

Asset Purchase 24

Eisai to Acquire Rights of Kolbet from Toyoma Chemical and Taisho Pharma 24

Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 25

Partnerships 26

Distributed Bio Enters into Collaboration with H3 Biomedicine 26

Eisai and MSD Enter into Co-Marketing Agreement 27

KAN Research Institute Enters into Development Agreement with Six Research Organizations 28

Eisai Enters into Research Agreement with Broad Institute, Colorado State University and University of Chicago 30

Eisai Enters into Development Agreement with Sloan Pharma 31

Eisai Enters into Agreement with Nichi-Iko Pharma 32

Eisai Enters into Co-Development and Co-Commercialization Agreement with Merck 33

Eisai and Boston University School of Medicine Enter into Research Agreement 34

Morphotek Enters into Research Agreement with Rockefeller University 35

Eisai Enters into Co-Promotion Agreement with Biogen 36

Sato Pharma, Eisai and Seren Pharma Enter into Agreement 37

EA Pharma and Mochida Pharma Enter into Joint Development Agreement 38

Ono Pharma Enters into Agreement with Eisai 39

Eisai Enters into Agreement with Merck 40

Morphotek Enters into Agreement with Johns Hopkins University School of Medicine 41

Eisai Enters into Agreement with Merck for Eribulin 42

Eisai Enters into Research Agreement with Broad Institute 43

Ewopharma and Eisai Enter into Co-Marketing Agreement 44

Oncology Venture and Eisai Enter into Agreement 45

Eisai Enters into Marketing and Distribution Agreement with Orion 46

Eisai Enters into Agreement with Keio University 47

Eisai Enters into Research Agreement with Oklahoma Medical Research Foundation 48

Morphotek Enters into Research Agreement with Fox Chase Cancer Center 49

Cancer Genetics Partners with H3 Biomedicine 50

Novartis Pharma Enters into Agreement with Eisai 51

EA Pharma Enters into Co-Promotion Agreement with AbbVie 52

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 53

Eisai Forms Joint Venture with Ajinomoto 55

Morphotek Enters into Agreement with Areva Med 56

Ajinomoto Pharma and Mochida Pharma Enter into Co-Development Agreement 57

Eisai Enters into Agreement with PIQUR Therapeutics 58

Eisai Extends Research Agreement with Charles River Labs 59

Eisai Enters into Agreement with Esteve 60

Morphotek Enters into Agreement with Mayo Clinic 61

Morphotek Enters into Research Agreement with University of Wisconsin Madison 62

Morphotek Enters into R&D Agreement with Targeted Alpha Therapy 63

Eisai Enters into Research Agreement with Medicines for Malaria Venture 64

Eisai Enters into Research Agreement with Liverpool School of Tropical Medicine and University of Liverpool 65

Eisai Enters into Research Agreement with Paoli Calmettes Institute 66

Eisai Enters into Agreement with Purdue Pharma 67

JCR Pharma Enters into Agreement with Eisai 68

Eisai Enters into Agreement with Nihon Medi-Physics 69

Kissei Pharma Enters into Co-Development Agreement with Ajinomoto Pharma 70

Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 71

AbbVie Deutschland Enters into Partnership Agreement with Eisai 72

Hikma Pharma Enters into Distribution Agreement with Eisai for Fycompa 73

Eisai Enters into Research Agreement with St. Jude Children's Research Hospital and Medicines For Malaria Venture to Develop SJ733 74

Eisai Enters into Research Agreement with Broad Institute 75

Eisai Enters into Agreement with Kyorin 76

Stealth Biologics Enters into Co-Development Agreement with Morphotek 77

Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek 78

Eisai and University of Tsukuba Enter into Co-Development Agreement 79

Eisai Enters Co-Development Agreement With Liverpool School Of Tropical Medicine And University of Liverpool 80

Eisai Expands Co-Development Agreement with Biogen 81

Eisai Enters into Co-Marketing Agreement with Esteve for Zonegran 83

Eisai Enters Into Co-Marketing Agreement With NewBridge Pharma For Halaven (Eribulin) 84

Eisai Enters Into Co-Development Agreement With Broad Institute For Neglected Tropical Diseases And Tuberculosis 85

Eisai Amends its Co-Marketing Agreement with Arena Pharma for Belviq 86

H3 Biomedicine Extends Agreement with Selvita 88

H3 Biomedicine And BGI Enter Into Agreement To Develop And Share Cancer Genomic Sequencing Data 89

H3 Biomedicine Enters Into Agreement With Sage Bionetworks For Cancer-Genomics Research 90

Eisai Enters Into Drug Discovery Agreement With University College London For Neurological Drugs 91

RaQualia Pharma Enters into Research Agreement with Ajinomoto Pharma 92

Eisai Enters Into R&D Agreement With Oswaldo Cruz Foundation For Malaria And Neglected Tropical Diseases 93

Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 94

Eisai Enters Into Agreement With Sabin Vaccine Institute To Develop Vaccines For Neglected Tropical Diseases 95

Verastem Enters Into Research Agreement With Eisai For Small Molecule Wnt Inhibitors 96

Galenea Enters Into Agreement With Eisai To Develop Synaptic Modulators for Neurodegenerative Diseases 97

MicroBiopharm Japan Enters Into Co-Development Agreement With Eisai 98

Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin 99

Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine 100

Proteros Biostructures Enters Into Drug Discovery Agreement With Eisai 101

Eisai Europe Enters Into Distribution Agreement With PharmaSwiss For Halaven 102

NanoCarrier Enters Into Co-Development Agreement With Eisai 103

Licensing Agreements 104

Eurofarma Labs Enters into Licensing Agreement with Eisai 104

BioArctic Receives Rights from Eisai 105

CY Biotech Enters into Licensing Agreement with Eisai 106

Tasly Pharma Enters into Licensing Agreement with EA Pharma 107

Morphotek Enters into Licensing Agreement with Bliss Biopharma 108

EA Pharma to Enter into Licensing Agreement with Cosmo Technologies 109

Adlai Nortye Biopharma Enters into Licensing Agreement with Eisai 110

JW Pharma Enters into Licensing Agreement with EA Pharma 111

Grupo Biotoscana Enters into Licensing Agreement with Eisai 112

Oncology Venture Enters into Licensing Agreement with Eisai 113

Eisai Enters into Licensing Agreement with Meiji Seika Pharma 114

EA Pharma Enters into Licensing Agreement with Calypso Biotech 115

Morphotek Enters into Licensing Agreement with Eurofarma Laboratorios 116

Dr. Reddy's Labs Enters into Licensing Agreement with Eisai for E7777 117

HUYA Bioscience International Enters into Licensing Agreement with Eisai 118

Eisai Enters into License Agreement with Amplyx Pharma 119

Roivant Sciences Enters into Licensing Agreement with Eisai 120

Blaze Bioscience Enters into Licensing Agreement with Morphotek 121

LTT Bio-Pharma Enters into License Agreement with Ajinomoto Pharma 122

Lantern Pharma Enters into Licensing Agreement with Eisai 123

Boston Strategics Enters into Licensing Agreement with Eisai for E6201 124

NanoCarrier Enters into Licensing Agreement with Eisai 125

Ajinomoto Pharma Amends Licensing Agreement with Albireo for Elobixibat 126

Otsuka Pharma Enters Into Licensing Agreement With Eisai 127

Accellta Enters into Licensing Agreement with Ajinomoto 128

Eisai To Enter Into Licensing Agreement With Nobelpharma For Antineoplastic Agent Gliadel 7.7Mg Implant 129

Eisai Enters Into Licensing Agreement With Generic Drug Manufacturer For Donepezil HCl 23mg 130

Ildong Enters Into Licensing Agreement With Ajinomoto Pharma For Cilnidipine/Valsartan Drug 131

Santen Pharma And Eisai Enter Into Option Agreement For Ophthalmic Drugs 132

Eisai Enters Into Licensing Agreement With Minophagen Pharma For Bexaroten 133

Institute for OneWorld Health Enters Into Licensing Agreement With Eisai For Pro-Drug Technology Patent 134

Compendia Bioscience Enters Into Licensing Agreement With H3 Biomedicine 135

Asset Transactions 136

Riemser Pharma Acquires European Rights to Prialt from Eisai 136

Concordia Pharmaceuticals Acquires Zonegran from Eisai for USD91.5 Million 137

Sarepta Therapeutics to Acquire Manufacturing Plant in Massachusetts from Eisai for USD15 Million 139

Eisai Taiwan Sells Tainan Production Plant To Bora 140

Valeant Pharma Acquires US Rights To Targretin From Eisai 141

Arbor Pharma To Acquire US Rights For Gliadel Wafer From Eisai 142

Acquisition 144

Dova Pharma Acquires AkaRx from Eisai 144

Eisai Acquires Liaoning TianYi Biological Pharma for USD78 Million 146

Alfresa to Acquire Sannova from Eisai 147

Sekisui Chemical to Acquire Eidia from Eisai for USD182 Million 148

Robert Bosch Completes Acquisiton Of Eisai Machinery 149

Eisai Co Ltd - Key Competitors 151

Eisai Co Ltd - Key Employees 152

Eisai Co Ltd - Locations And Subsidiaries 155

Head Office 155

Other Locations & Subsidiaries 155

Joint Venture 157

Recent Developments 159

Strategy And Business Planning 159

Nov 08, 2018: Eisai commences full-scale operation of new suzhou plant in China 159

Jun 13, 2018: Eisai To Establish New Research Facility Eisai Center For Genetics Guided Dementia Discovery In Cambridge, Massachusetts In The United States 160

Jan 11, 2018: Eisai Completes Construction Of Oral Solid Dose Production Facility At New Suzhou Plant In China 161

Corporate Communications 162

Oct 10, 2018: Eisai to support earthquake relief efforts in sulawesi, indonesia 162

Jul 18, 2018: Eisai supports relief efforts for flooding in western Japan 163

Jun 11, 2018: Eisai Names Lihua Yu As President & Chief Data Sciences Officer Of H3 Biomedicine 164

Sep 25, 2017: Eisai to Contribute to Central Mexican Earthquake Relief Efforts 165

Apr 05, 2017: Eisai and Meiji to commercialise safinamide for Parkinsons disease in Japan and Asia 166

Government and Public Interest 167

Oct 31, 2017: GHIT Fund Accelerates Promising Efforts to Find New Treatments, Vaccines and Diagnostics for Malaria, Tuberculosis, Leishmaniasis and Mycetoma 167

Jun 28, 2017: Eisai Listed for 16th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment 170

Jan 18, 2017: Eisai To Participate In Access Accelerated, Global Partnership To Address Rise Of Non-Communicable Diseases 171

Product News 172

12/07/2017: Eisai and Purdue Pharma L.P. Presented Lemborexant Data from Research Studies at ACNP Annual Meeting 172

10/31/2017: Eisai To Present Latest Data On lemborexant At 10th Clinical Trials On Alzheimer's Disease 173

10/24/2018: Eisai to present discovery of a structurally novel class of STING agonist E7766 at SITC's 33rd Annual Meeting 174

Oct 19, 2018: Discovery of candidate compound as potential treatment for parkinson's disease using ips cellsopening the way to establishing new techniques for developing treatments for neurological diseases 175

Oct 10, 2017: Small And Easy To Take, Just One Tablet Per Dose Eisai To Launch Onji-No-Megumi For Improving Forgetfulness In Middle Age And Beyond 177

09/11/2017: Eisai Presents Results of Phase Ib/II Clinical Study of Lenvima in Combination With Pembrolizumab for Renal Cell Carcinoma in Oral Session at ESMO 2017 Congress 178

07/17/2017: Eisai Presents Poster on BAN2401 at the 2017 Alzheimer's Association International Conference 180

06/15/2017: Inhibitor Drug Improves Overall Survival in Older Radioiodine Resistant Thyroid Cancer Patients 181

06/05/2017: Eisai to Present Results of Phase Ib/II Study of Anticancer Agent Lenvima (Lenvatinib) in Combination With Anti-PD-1 Antibody Pembrolizumab for the Treatment of Endometrial Carcinoma at 53rd ASCO Annual Meeting 182

06/02/2017: Further Study of Combination of Eisais Lenvatinib and Mercks Pembrolizumab in Previously Treated Patients with Metastatic Endometrial Cancer Supported by Interim Analysis of Ongoing Phase 1b/2 Trial 184

04/05/2017: Eisai Presents Data Of Mechanisms Of Action Relating To Tumor Immune Response Regarding Combination Of Anticancer Agent Lenvatinib With Anti-PD-1 Antibody At AACR 108th Annual Meeting 186

03/28/2017: Eisai to Present Data on Lenvima at 2017 AACR Annual Meeting 187

03/28/2017: German Federal Joint Committee (G-BA) Confirms Additional Benefit of Kisplyx (lenvatinib) in Treatment of Advanced Renal Cell Carcinoma 189

03/23/2018: Anticancer Agent LENVIMA (lenvatinib mesylate) Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC 190

03/12/2018: Grupo Biotoscana Announces New Initiatives for LENVIMA 191

01/09/2018: Eisai and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA (lenvatinib mesylate) and KEYTRUDA (pembrolizumab) as Combination Therapy for Advanced and/or Metastatic Renal Cell Carcinoma 192

01/04/2017: German Institute for Quality and Efficiency in Health Care Confirms Additional Benefit for Kisplyx (lenvatinib) in Combination with everolimus for the Treatment of Advanced Renal Cell Carcinoma 194

01/03/2018: Clinigen Seeks Marketing Authorisation and Launch Lenvima in Africa 196

Product Approvals 197

Feb 16, 2018: UK NICE Recommends Anticancer Agent Lenvima as Treatment for Thyroid Cancer 197

Jan 26, 2018: NICE Issues Technology Appraisal Guidance on Lenvatinib with Everolimus for Previously Treated Advanced RCC 198

Dec 27, 2017: Anticancer Agent Lenvatinib Designated For Priority Review And Approval By China Food And Drug Administration For Hepatocellular Carcinoma 200

Dec 11, 2017: Eisai salutes positive NICE Recommendation for Kisplyx (lenvatinib) for the treatment of advanced renal cell carcinoma 201

Dec 06, 2017: Eisai Submits Application For Expanded Indication Covering Hepatocellular Carcinoma For Anticancer Agent Lenvima In Taiwan 202

Oct 31, 2017: New Drug Application Of Anticancer Agent Lenvatinib For Hepatocellular Carcinoma Accepted In China 203

Sep 27, 2017: Application for Additional Indication of Lenvima for Hepatocellular Carcinoma Accepted for Review by U.S. FDA 205

Sep 26, 2017: FDA Accepts Supplemental New Drug Application for Eisais Lenvatinib for the Treatment of Liver Cancer 207

Jul 25, 2017: Eisai submits simultaneous applications in the united states and europe for lenvatinib in hepatocellular carcinoma 209

Jun 23, 2017: Eisai Submits Application For Additional Indication Of Anticancer Agent Lenvima For Hepatocellular Carcinoma In Japan 210

Clinical Trials 212

Sep 14, 2018: 1.5M to develop candidate drug to treat onchocerciasis and lymphatic filariasis 212

May 22, 2018: Eisai and Purdue Pharma Announce Key Phase 1 Clinical Studies of Lemborexant to be Presented at the 32nd Annual SLEEP Meeting 213

Mar 07, 2018: Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant 215

Feb 15, 2018: Positive Phase 3 Trial Results of Investigational Anticancer Agent Lenvatinib in Unresectable Hepatocellular Carcinoma (HCC) Published in The Lancet 217

Feb 10, 2018: Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in the Lancet 219

Jan 22, 2018: Eisai Presents Results of Analysis of Phase III Trial of Lenvima (Lenvatinib) In Hepatocellular Carcinoma Based on Independent Imaging Review at ASCO-GI 220

Dec 21, 2017: BioArctic announces that the Phase 2b study of BAN2401 in early Alzheimers Disease continues toward 18 month endpoint 222

Sep 29, 2017: Eisai Presents Results of Phase III Trial of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma in Oral Session at 20th CSCO Annual Meeting 224

Sep 19, 2017: Eisai Presents Results Of Phase III Clinical Study Of Lenvima (Lenvatinib) In Unresectable Hepatocellular Carcinoma At 11th ILCA Annual Conference 226

Sep 11, 2017: Eisai Presents New Quality of Life Findings in Hepatocellular Carcinoma Patients from Lenvatinib Versus Sorafenib Study in Oral Session at ESMO Congress 228

Sep 01, 2017: Eisai to Present 3 Abstracts on Lenvima at ESMO 2017 Congress 230

Sep 01, 2017: Eisai to Present Abstract on E7046 at ESMO 2017 Congress 232

Sep 01, 2017: Eisai to Present Abstract on its Oncology Product Candidate E7046 at the ESMO 2017 Congress 233

Sep 01, 2017: Eisai To Present Abstracts On Oncology Products And Pipeline At ESMO 2017 Congress 234

Aug 28, 2017: Lenvatinib Significantly Improved Overall Survival in Older Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer According to Results of Subanalysis of Phase 3 SELECT Trial 236

Jul 17, 2017: Eisai Presents 3 Posters on E2027 at the 2017 Alzheimer's Association International Conference 238

Jun 05, 2017: Eisai to Present Results of Phase III Trial of Lenvima (Lenvatinib) as First-line Treatment for Unresectable Hepatocellular Carcinoma in Oral Session at 53rd Asco Annual Meeting 239

Jun 04, 2017: Lenvatinib Demonstrates Positive Results vs Sorafenib Across All Endpoints in First-Line Phase 3 Non-inferiority Trial of Unresectable Hepatocellular Carcinoma (uHCC) 241

May 18, 2017: Eisai to Present Abstracts on Lenvatinib At 53rd ASCO Annual Meeting 243

Jan 25, 2017: Phase III Trial Of Anticancer Agent Lenvima As First-Line Treatment For Unresectable Hepatocellular Carcinoma Meets Primary Endpoint 244

Appendix 245

Methodology 245

About GlobalData 245

Contact Us 245

Disclaimer 245


List Of Figure

List of Figures

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 12

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14

Eisai Co Ltd, Medical Devices Deals, 2012 to YTD 2018 16


List Of Table

List of Tables

Eisai Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Eisai Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Eisai Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 14

Eisai Co Ltd, Medical Devices Deals, 2012 to YTD 2018 16

Eisai Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17

Eisai to Acquire Rights of Kolbet from Toyoma Chemical and Taisho Pharma 24

Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 25

Distributed Bio Enters into Collaboration with H3 Biomedicine 26

Eisai and MSD Enter into Co-Marketing Agreement 27

KAN Research Institute Enters into Development Agreement with Six Research Organizations 28

Eisai Enters into Research Agreement with Broad Institute, Colorado State University and University of Chicago 30

Eisai Enters into Development Agreement with Sloan Pharma 31

Eisai Enters into Agreement with Nichi-Iko Pharma 32

Eisai Enters into Co-Development and Co-Commercialization Agreement with Merck 33

Eisai and Boston University School of Medicine Enter into Research Agreement 34

Morphotek Enters into Research Agreement with Rockefeller University 35

Eisai Enters into Co-Promotion Agreement with Biogen 36

Sato Pharma, Eisai and Seren Pharma Enter into Agreement 37

EA Pharma and Mochida Pharma Enter into Joint Development Agreement 38

Ono Pharma Enters into Agreement with Eisai 39

Eisai Enters into Agreement with Merck 40

Morphotek Enters into Agreement with Johns Hopkins University School of Medicine 41

Eisai Enters into Agreement with Merck for Eribulin 42

Eisai Enters into Research Agreement with Broad Institute 43

Ewopharma and Eisai Enter into Co-Marketing Agreement 44

Oncology Venture and Eisai Enter into Agreement 45

Eisai Enters into Marketing and Distribution Agreement with Orion 46

Eisai Enters into Agreement with Keio University 47

Eisai Enters into Research Agreement with Oklahoma Medical Research Foundation 48

Morphotek Enters into Research Agreement with Fox Chase Cancer Center 49

Cancer Genetics Partners with H3 Biomedicine 50

Novartis Pharma Enters into Agreement with Eisai 51

EA Pharma Enters into Co-Promotion Agreement with AbbVie 52

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 53

Eisai Forms Joint Venture with Ajinomoto 55

Morphotek Enters into Agreement with Areva Med 56

Ajinomoto Pharma and Mochida Pharma Enter into Co-Development Agreement 57

Eisai Enters into Agreement with PIQUR Therapeutics 58

Eisai Extends Research Agreement with Charles River Labs 59

Eisai Enters into Agreement with Esteve 60

Morphotek Enters into Agreement with Mayo Clinic 61

Morphotek Enters into Research Agreement with University of Wisconsin Madison 62

Morphotek Enters into R&D Agreement with Targeted Alpha Therapy 63

Eisai Enters into Research Agreement with Medicines for Malaria Venture 64

Eisai Enters into Research Agreement with Liverpool School of Tropical Medicine and University of Liverpool 65

Eisai Enters into Research Agreement with Paoli Calmettes Institute 66

Eisai Enters into Agreement with Purdue Pharma 67

JCR Pharma Enters into Agreement with Eisai 68

Eisai Enters into Agreement with Nihon Medi-Physics 69

Kissei Pharma Enters into Co-Development Agreement with Ajinomoto Pharma 70

Foundation Medicine Extends its Co-Development Agreement with H3 Biomedicine 71

AbbVie Deutschland Enters into Partnership Agreement with Eisai 72

Hikma Pharma Enters into Distribution Agreement with Eisai for Fycompa 73

Eisai Enters into Research Agreement with St. Jude Children's Research Hospital and Medicines For Malaria Venture to Develop SJ733 74

Eisai Enters into Research Agreement with Broad Institute 75

Eisai Enters into Agreement with Kyorin 76

Stealth Biologics Enters into Co-Development Agreement with Morphotek 77

Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek 78

Eisai and University of Tsukuba Enter into Co-Development Agreement 79

Eisai Enters Co-Development Agreement With Liverpool School Of Tropical Medicine And University of Liverpool 80

Eisai Expands Co-Development Agreement with Biogen 81

Eisai Enters into Co-Marketing Agreement with Esteve for Zonegran 83

Eisai Enters Into Co-Marketing Agreement With NewBridge Pharma For Halaven (Eribulin) 84

Eisai Enters Into Co-Development Agreement With Broad Institute For Neglected Tropical Diseases And Tuberculosis 85

Eisai Amends its Co-Marketing Agreement with Arena Pharma for Belviq 86

H3 Biomedicine Extends Agreement with Selvita 88

H3 Biomedicine And BGI Enter Into Agreement To Develop And Share Cancer Genomic Sequencing Data 89

H3 Biomedicine Enters Into Agreement With Sage Bionetworks For Cancer-Genomics Research 90

Eisai Enters Into Drug Discovery Agreement With University College London For Neurological Drugs 91

RaQualia Pharma Enters into Research Agreement with Ajinomoto Pharma 92

Eisai Enters Into R&D Agreement With Oswaldo Cruz Foundation For Malaria And Neglected Tropical Diseases 93

Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 94

Eisai Enters Into Agreement With Sabin Vaccine Institute To Develop Vaccines For Neglected Tropical Diseases 95

Verastem Enters Into Research Agreement With Eisai For Small Molecule Wnt Inhibitors 96

Galenea Enters Into Agreement With Eisai To Develop Synaptic Modulators for Neurodegenerative Diseases 97

MicroBiopharm Japan Enters Into Co-Development Agreement With Eisai 98

Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin 99

Horizon Discovery Enters Into Co-Development Agreement With H3 Biomedicine 100

Proteros Biostructures Enters Into Drug Discovery Agreement With Eisai 101

Eisai Europe Enters Into Distribution Agreement With PharmaSwiss For Halaven 102

NanoCarrier Enters Into Co-Development Agreement With Eisai 103

Eurofarma Labs Enters into Licensing Agreement with Eisai 104

BioArctic Receives Rights from Eisai 105

CY Biotech Enters into Licensing Agreement with Eisai 106

Tasly Pharma Enters into Licensing Agreement with EA Pharma 107

Morphotek Enters into Licensing Agreement with Bliss Biopharma 108

EA Pharma to Enter into Licensing Agreement with Cosmo Technologies 109

Adlai Nortye Biopharma Enters into Licensing Agreement with Eisai 110

JW Pharma Enters into Licensing Agreement with EA Pharma 111

Grupo Biotoscana Enters into Licensing Agreement with Eisai 112

Oncology Venture Enters into Licensing Agreement with Eisai 113

Eisai Enters into Licensing Agreement with Meiji Seika Pharma 114

EA Pharma Enters into Licensing Agreement with Calypso Biotech 115

Morphotek Enters into Licensing Agreement with Eurofarma Laboratorios 116

Dr. Reddy's Labs Enters into Licensing Agreement with Eisai for E7777 117

HUYA Bioscience International Enters into Licensing Agreement with Eisai 118

Eisai Enters into License Agreement with Amplyx Pharma 119

Roivant Sciences Enters into Licensing Agreement with Eisai 120

Blaze Bioscience Enters into Licensing Agreement with Morphotek 121

LTT Bio-Pharma Enters into License Agreement with Ajinomoto Pharma 122

Lantern Pharma Enters into Licensing Agreement with Eisai 123

Boston Strategics Enters into Licensing Agreement with Eisai for E6201 124

NanoCarrier Enters into Licensing Agreement with Eisai 125

Ajinomoto Pharma Amends Licensing Agreement with Albireo for Elobixibat 126

Otsuka Pharma Enters Into Licensing Agreement With Eisai 127

Accellta Enters into Licensing Agreement with Ajinomoto 128

Eisai To Enter Into Licensing Agreement With Nobelpharma For Antineoplastic Agent Gliadel 7.7Mg Implant 129

Eisai Enters Into Licensing Agreement With Generic Drug Manufacturer For Donepezil HCl 23mg 130

Ildong Enters Into Licensing Agreement With Ajinomoto Pharma For Cilnidipine/Valsartan Drug 131

Santen Pharma And Eisai Enter Into Option Agreement For Ophthalmic Drugs 132

Eisai Enters Into Licensing Agreement With Minophagen Pharma For Bexaroten 133

Institute for OneWorld Health Enters Into Licensing Agreement With Eisai For Pro-Drug Technology Patent 134

Compendia Bioscience Enters Into Licensing Agreement With H3 Biomedicine 135

Riemser Pharma Acquires European Rights to Prialt from Eisai 136

Concordia Pharmaceuticals Acquires Zonegran from Eisai for USD91.5 Million 137

Sarepta Therapeutics to Acquire Manufacturing Plant in Massachusetts from Eisai for USD15 Million 139

Eisai Taiwan Sells Tainan Production Plant To Bora 140

Valeant Pharma Acquires US Rights To Targretin From Eisai 141

Arbor Pharma To Acquire US Rights For Gliadel Wafer From Eisai 142

Dova Pharma Acquires AkaRx from Eisai 144

Eisai Acquires Liaoning TianYi Biological Pharma for USD78 Million 146

Alfresa to Acquire Sannova from Eisai 147

Sekisui Chemical to Acquire Eidia from Eisai for USD182 Million 148

Robert Bosch Completes Acquisiton Of Eisai Machinery 149

Eisai Co Ltd, Key Competitors 151

Eisai Co Ltd, Key Employees 152

Eisai Co Ltd, Subsidiaries 155

Eisai Co Ltd, Joint Venture 157

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Eisai Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.